Ibogaine vs Mushrooms: What the Difference Actually Is

Ibogaine and psilocybin mushrooms are both described as psychedelic medicines used for addiction and mental health. The description ends there. They act on different receptor systems, produce experiences of different lengths and character, and address different conditions most effectively. Treating them as alternatives — as though the decision between them is a matter of personal preference — misses the mechanism differences that make each medicine what it is.

How Ibogaine and Psilocybin Work Differently

Ibogaine and psilocybin share a structural category — both are indole alkaloids — and little else in terms of how they act on the brain.

Psilocybin acts primarily through the 5-HT2A serotonin receptor. That binding decreases activity in the default mode network — the brain's self-referential processing system. Rigid negative thought patterns and the sense that the current version of a person's situation is the only possible one emerge partly from an overactive default mode network. Psilocybin disrupts that activity. It also increases BDNF (brain-derived neurotrophic factor), which supports the formation of new neural connections. The result is a period of increased neuroplasticity following the experience.

Ibogaine acts on at least six distinct receptor systems simultaneously: kappa-opioid, mu-opioid, NMDA, sigma-2, serotonin, and dopamine. The mu-opioid receptor binding is what produces its defining effect on opioid dependence: ibogaine displaces opioids from those receptors and normalises the dopaminergic dysregulation that chronic use creates. It does not manage withdrawal gradually. It interrupts it — within hours. That pharmacological breadth is why ibogaine's effects persist long after the substance has cleared the system.

Both medicines increase neuroplasticity. The mechanisms, the receptor systems involved, and the clinical applications that follow from each are not interchangeable. Psilocybin does not touch opioid receptors. Ibogaine does not produce the default mode network disruption that characterises the psilocybin experience. They are not the same type of intervention.

What Each Medicine Is Used For

Ibogaine has the strongest clinical evidence for opioid use disorder. No approved treatment approaches what ibogaine does at the receptor level — directly displacing opioids and interrupting the craving architecture that opioid dependence creates. For PTSD, traumatic brain injury, and treatment-resistant depression, the 2023 Stanford study published in Nature Medicine measured outcomes at one month following ibogaine treatment in 30 special operations veterans: an average 88% decrease in PTSD symptoms, 87% in depression symptoms, and 81% in anxiety. Conventional antidepressant research considers a 50% reduction in depression scores a strong response. Texas subsequently committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M, and Baylor.

Those numbers have real limitations: 30 participants is not a large population, there was no placebo arm, and the findings apply to a specific population with treatment-resistant conditions. The direction is consistent enough that states are now allocating institutional funding to replicate and expand it.

Psilocybin has a different evidence base. Johns Hopkins clinical trials found 80% abstinence at six months for tobacco cessation — substantially higher than any approved pharmacotherapy for smoking. Trials for alcohol use disorder show consistent reductions in heavy drinking days. For depression, anxiety, and existential distress — including in people facing terminal diagnoses — psilocybin has produced outcomes driving regulatory interest in multiple countries.

For opioid dependence specifically: psilocybin offers no equivalent to ibogaine. It does not act on opioid receptors and cannot interrupt opioid withdrawal or the receptor dysregulation that chronic opioid use produces. The two medicines are not alternatives for this condition.

The people who arrive at iboga ceremony with the clearest outcomes are often those who spent years trying everything else — SSRIs that blunted rather than resolved, therapy that circled without landing, abstinence-based programmes that held for months and then didn't. By the time they sit with ibogaine, they have evidence that conventional approaches have not been enough. That scepticism, earned over years, tends to produce people who are ready to work with what the experience shows them rather than what they hoped it would.

Duration and Intensity

Ibogaine onset: 1–2 hours after administration. Active experience: 12–24 hours across three phases. Recovery: 2–3 days.

The first phase (hours 1–8) is the most physically demanding: ataxia is common, nausea occurs in some participants, and lying still is strongly advised. Eyes-closed imagery is typically autobiographical — significant memories, unresolved material, and patterns from the person's life presented with unusual clarity and without the usual emotional distance. The second phase (hours 8–24) shifts toward internal processing — less dramatic in content, often more substantively significant in terms of what it produces. Residual stimulation — difficulty sleeping, light sensitivity, heightened emotional sensitivity — persists for 48–72 hours post-ceremony.

Psilocybin onset: 30–60 minutes. Peak: 2–3 hours. Full experience: 4–6 hours. Recovery: typically same-day for most people.

The shorter duration does not mean a gentler experience. Psilocybin produces ego dissolution, perceptual distortion, and confrontation with difficult psychological content — sometimes substantially challenging depending on set, setting, and the individual. Multiple sessions are typically required for lasting change; clinical protocols often use two to three sessions over several weeks. A single ibogaine ceremony is more typically the primary intervention.

People who come expecting psilocybin to be the easier option because it ends sooner are usually not correct. The medicine does not accommodate that expectation. Neither does ibogaine — through a different mechanism, across a different timeline.

Safety and Medical Requirements

Ibogaine has real cardiac risk. It prolongs the QT interval — the electrical period during which the heart repolarises. For people with existing QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction, this is an absolute contraindication — not a caution to manage, but a reason the medicine cannot be administered safely. EKG and cardiovascular assessment are required before every ibogaine ceremony.

Any ibogaine provider who skips cardiac screening is not operating safely. Providers who skip it exist. The cost of an on-site medical professional and proper screening is real — providers charging significantly below market rate are almost always cutting that infrastructure, not being generous. This is not a stylistic difference between providers. It is the difference between a ceremony and a fatality.

Psilocybin is physiologically safer. The cardiac risk is substantially lower. The primary risks are psychological: people with personal or family history of psychosis or schizophrenia spectrum disorder face real risk of destabilisation, and the experience can be intensely confronting even in people without that history.

Both medicines have contraindications for SSRIs and SNRIs, for different reasons. With psilocybin, SSRIs blunt the serotonin response — the experience is diminished or absent. With ibogaine, the interaction risk is potentially fatal. A supervised taper, coordinated with the prescribing physician, is required before ibogaine ceremony is possible. One week off SSRIs before ceremony is not a taper. It is a risk.

Cost and Legal Status in Canada

Ibogaine is not listed under Canada's Controlled Drugs and Substances Act — it is not explicitly prohibited. This is a meaningfully different legal position from the United States, where ibogaine is Schedule I, or the United Kingdom, where it is Class A. Ibogaine ceremony at ExploreBwiti in Vancouver costs $2,000–$5,000 CAD, which includes the on-site medical professional, medicine, and facilitation. Integration coaching costs $150–$300 per session (60–90 minutes).

Psilocybin in Canada is a controlled substance. Legal access outside of clinical trials requires an exemption through Health Canada's Special Access Program, available for certain treatment-resistant populations. A small number of licensed psilocybin therapy services operate under this framework. Costs vary significantly by provider.

The regulatory environment for both medicines is shifting. The relevant comparison for someone making a decision now is the access that currently exists — which differs substantially between the two.

Who This Is Not For

The following are absolute contraindications for ibogaine. None of them can be worked around:

• QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine prolongs the QT interval. This is the mechanism behind cardiac fatalities in ibogaine treatment. EKG screening identifies this before the ceremony, not during it.
• Current SSRIs or SNRIs. Serotonin syndrome risk is real and potentially fatal. A supervised taper — coordinated with your prescribing physician — is required before ceremony is possible. There are no exceptions. If a provider tells you that stopping SSRIs for one week before ceremony is sufficient, that provider is not managing this safely.
• Methadone. A specific supervised transition protocol is required. This takes weeks to months — not days.
• Severe liver or kidney disease. Ibogaine is metabolised through hepatic pathways that must be functioning adequately.
• Active psychosis or acute psychiatric instability. The experience amplifies what is present. Entering ceremony in crisis does not produce stability.
• Pregnancy.

For both ibogaine and psilocybin: personal or family history of schizophrenia or psychosis spectrum disorder is a contraindication for either medicine.

Someone primarily seeking a shortcut to insight is not an appropriate candidate for either medicine. Iboga does not deliver what people hope for — it tends to deliver what they need, which is often not the same thing. People who arrive expecting a pleasant or expansive altered state are consistently surprised by how direct the experience is.

Read the FAQ for a direct account of what screening involves and what disqualifies someone from ceremony.

Is This Right for You?

The comparison between ibogaine and psilocybin is not a question of which is better. It is a question of which — if either — applies to the specific condition and the specific person.

For opioid dependence: ibogaine is the only medicine with direct receptor-level evidence. For tobacco cessation or alcohol use disorder where the mechanism is primarily psychological rather than neurochemical: psilocybin has stronger clinical trial data. For PTSD and treatment-resistant depression in people who have already tried conventional treatment: both show evidence, and the choice depends on the medical picture and which contraindications apply.

That assessment requires an honest inventory of your medical history, current medications, and what you are actually trying to address. It also requires a provider who will tell you directly if you are not an appropriate candidate — rather than accommodating everyone who applies.

The ceremony page describes iboga and 5-MeO-DMT ceremony at ExploreBwiti specifically. The FAQ covers what medical screening involves. The integration page describes what the post-ceremony work looks like. The opioid addiction guide goes deeper on ibogaine's evidence base for opioid dependence. When you are ready to begin the conversation, the application is where it starts — we respond personally to every application within 2–3 business days.

If you are currently on SSRIs, start with your prescribing physician and a conversation about what a supervised taper would involve and whether the timeline is feasible. It may not be. That is not a comfortable answer. It is the accurate one.